MedTrace Logo

Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

NCT07747935 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-08-05

No results posted yet for this study

Summary

Neoadjuvant RBP-01 in patients with primary uveal melanoma.

Conditions

Interventions

DRUG

RBP-01

Each RBP-01 dose consists of a 5 µL intravitreal injection conjugating 250 µg of sotrastaurin.

Sponsors & Collaborators

  • ReBio Pharma

    lead INDUSTRY

Principal Investigators

  • Ido Didi Fabian, Prof. · Sheba Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2028-04-01
Completion
2028-04-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07747935 on ClinicalTrials.gov